NEJM Clinical Practice Center: Review: Psoriatic arthritis occurs in up to 30% of people with psoriasis and can have serious debilitating effects on the peripheral joints, spine, tendon insertions, and fingers. Management has improved, but complete disease control is not yet achievable.
Category: Psoriatic Arthritis
Samsung Bioepis wins UK patent suit against AbbVie’s Humira
… in 2015. “We welcome the court’s judgment. At Samsung Bioepis, we remain committed to driving positive change in the health care system through the development of affordable, high-quality biosimilars,” Samsung Bioepis said in a statement. The UK …
Celgene to Present New Data from Clinical Trials on Oral OTEZLA…
Celgene Corporation today announced that findings from ongoing clinical trials of OTEZLA , the Company’s oral, selective inhibitor of phosphodiesterase 4 , conducted in patients with moderate or moderate to severe plaque psoriasis, and in adult patients with active psoriatic arthritis, will be presented at the 75th Annual Meeting of the American Academy of Dermatology in Orlando, Florida. Ten abstracts will be presented at the meeting.
How Big Is the Opportunity for Celgene’s Otezla Overseas?
Since winning approval for use in psoriasis in September 2014, Otezla has steadily been chipping away at U.S. market share in the indication, turning into a billion-dollar blockbuster in the process. Otezla’s sales continued climbing throughout 2016, and with launches planned in new international markets soon, sales could head even higher.